- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07490093
Adaptation Strategies for Coping With the Impact of Sensory Alterations on Eating Behavior in Children With Cancer: A Qualitative Study From the Perspective of Children and Parents (QUALISENS)
Childhood cancer is a serious and life-changing disease that affects thousands of children every year worldwide. In addition to the disease itself, cancer treatments such as chemotherapy often cause difficult side effects. Among these, changes in taste and smell are very common but still poorly understood in children. These sensory changes can make food taste unpleasant or smell different, leading children to eat less, avoid certain foods, or develop strong food aversions. As a result, many children with cancer experience weight loss, poor nutrition, and reduced quality of life, which can also affect how well they tolerate treatment.
Research suggests that between 40% and 60% of children with cancer struggle to maintain good nutritional status during treatment. Taste and smell alterations play a major role in these difficulties. Children may experience nausea triggered by food smells, changes in food texture perception, or a loss of pleasure in eating. Parents often report feeling powerless and lacking clear guidance on how to help their child cope with these problems.
While taste and smell disturbances have been widely studied in adults with cancer, much less is known about how children experience these changes and, importantly, how they and their families adapt to them. Parents play a key role in supporting their child's eating habits, but their perspectives may differ from the child's own experiences.
This study aims to better understand how children undergoing chemotherapy and their parents perceive changes in taste, smell, and food texture, and how these changes affect eating behavior, emotions, and social life. Using individual semi-structured interviews, the study will explore the coping strategies used by children and parents to manage these sensory changes, both at home and in the hospital setting.
By giving children and parents a voice, this research seeks to identify practical, real-life strategies that families find helpful. The results will contribute to improving nutritional support and guidance for children with cancer, with the ultimate goal of enhancing their well-being, quality of life, and treatment outcomes.
Study Overview
Status
Intervention / Treatment
Detailed Description
Childhood cancer represents a major public health concern and remains one of the leading causes of disease-related mortality in children. Advances in treatment have improved survival, but chemotherapy is frequently associated with adverse effects that significantly impact nutritional status and quality of life. Malnutrition affects approximately 40-60% of pediatric oncology patients and is associated with poorer treatment tolerance, increased risk of infection, immune dysfunction, and reduced survival.
Among treatment-related toxicities, alterations in taste (dysgeusia) and smell (dysosmia) are increasingly recognized as key contributors to feeding difficulties. Chemotherapy targets rapidly dividing cells, including gustatory and olfactory receptor cells, which may explain the high prevalence of sensory disturbances. Taste and smell play a central role in appetite regulation and food enjoyment; their disruption can lead to reduced intake, food aversions, and changes in texture preferences. Although these effects are well documented in adults, pediatric data remain limited and heterogeneous, particularly regarding children's subjective experiences and coping mechanisms.
Recent studies suggest that up to 60% of children receiving chemotherapy experience taste and/or smell alterations perceived as highly distressing. Adolescents frequently report that food "does not taste good" and that food-related smells trigger nausea. Parents often identify sensory changes as the main cause of feeding problems, yet discrepancies may exist between parental perceptions and children's lived experiences. Furthermore, little is known about how food texture perception evolves in children with cancer, despite evidence that tactile oral sensitivity can strongly influence food selectivity.
This study is designed as a prospective, monocentric, non-interventional observational study (RIPH3), using a qualitative methodology based on individual semi-structured interviews. Participants will include children aged 6-17 years undergoing chemotherapy for a malignant hematological or solid tumor, and one of their parents or legal guardians. Interviews will be conducted separately with children and parents to ensure independent data collection and minimize mutual influence. Fifteen children and one of their parent will be included.
The primary objective is to identify and describe the coping strategies used by children and parents to manage taste, smell, and texture alterations and associated changes in eating behavior during chemotherapy. Secondary objectives include characterizing the nature, frequency, intensity, and duration of reported sensory alterations; exploring their emotional and social impact; examining the influence of cancer type, treatment stage, and eating context (hospital versus home); and assessing concordance and discrepancies between children's and parents' experiences and descriptions.
Data analysis will follow a rigorous qualitative approach, including thematic coding, verification of code saturation, and cross-checking by a second researcher to ensure analytical reliability. Reflexivity will be supported through the use of a field journal documenting the researcher's observations and potential biases.
This study will be among the first qualitative investigations in France to focus specifically on chemo-sensory alterations in pediatric oncology from both the child's and the parent's perspectives. By identifying effective, family-driven coping strategies, the findings aim to inform future nutritional guidance, supportive care interventions, and clinical recommendations, ultimately improving nutritional outcomes and quality of life for children undergoing cancer treatment.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Samia Saraya
- Phone Number: +33767889375
- Email: ssaraya-jean@institutlyfe.com
Study Contact Backup
- Name: Séverine Bouttefroy
- Email: severine.bouttefroy@ihope.fr
Study Locations
-
-
-
Lyon, France, 69008
- Institut d'Hématologie et d'Oncologie Pédiatrique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
History of cancer
Any cognitive impairment or condition that may limit the use of numerical scales and quality of life questionnaires, including but not limited to:
Children with neurodevelopmental disorders such as autism or Down syndrome These children may have specific cognitive or communication characteristics that require specialized interview techniques. Their inclusion could complicate data comparability and introduce confounding factors. This exclusion ensures data quality and consistency, while respecting the well-being of participants.
Patients for whom other types of cancer treatment are planned during the study period (e.g., radiation therapy) Patients in relapse Presence of a pre-existing pediatric eating disorder or pre-existing food selectivity
Description
Inclusion Criteria:
Children:
- Aged 6 to 17 years old on the day consent is obtained.
- Diagnosed with a malignant hematological or oncological tumor.
- Possessing sufficient verbal ability to participate in the interview planned for the study.
- Having started chemotherapy treatment at least 2 months prior.
- Agreeing to participate in the study.
- Able to understand, read, and write French.
- Affiliated with a social security system.
Parents:
- Be the parent or legal guardian of a child aged 6 to 17 inclusive, with cancer and undergoing chemotherapy.
- Dated and signed informed consent.
- Able to understand, read, and write French.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
children aged 6-17 years undergoing chemotherapy for a malignant hematological or solid tumor
|
no intervention
|
|
one of the parent of the children included in the first group
|
no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
coping strategies of the children and their parents for managment of sensory alterations and eating behaviour
Time Frame: at least 2 months after the beginning of the chemotherapy
|
Determine the coping strategies used by children and their parents to manage sensory alterations and eating behavior during chemotherapy. the method for the thematic analysis of qualitative data described by Braun and Clarke will be used |
at least 2 months after the beginning of the chemotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine the effectiveness and purpose of these strategies.
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
|
Characterize the sensory alterations reported by children undergoing chemotherapy
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
|
Identify the frequency, reported intensity, and duration of alterations in taste, smell, and texture, and their role in eating behavior in children undergoing chemotherapy.
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
|
Determine the influence of cancer type and eating environment (hospital or home) on food perception
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
|
Study the impact of treatment type and stage on food perception and eating behavior.
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
|
Assess the role of sensory alterations on children's quality of life, particularly their emotional and social well-being.
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
|
Determine the relationship between the experiences of children and their parents by identifying their awareness of problems and their ability to describe them accurately.
Time Frame: at least 2 months after the beginning of the chemotherapy
|
the method for the thematic analysis of qualitative data described by Braun and Clarke will be used
|
at least 2 months after the beginning of the chemotherapy
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Anestis Dougkas, Institut Lyfe
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET25-318
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smell Disorder
-
Universitaire Ziekenhuizen KU LeuvenRecruitingTaste Disorders | Olfactory Disorder | Smell Disorder | Smell DysfunctionBelgium
-
RespiralabNot yet recruiting
-
Ataturk UniversityRecruiting
-
Ministry of Health, Saudi ArabiaNot yet recruitingTaste Disorders | Smell Disorder | Smell Dysfunction | Taste Disorder, Secondary, Sweet | Taste Disorder, Secondary, Bitter
-
Pamela Youde Nethersole Eastern HospitalRecruitingAnosmia | Olfaction Disorders | Hyposmia | Smell Disorders | Smell Loss | Smell Dysfunction | Olfactory ImpairmentHong Kong
-
Médipôle Lyon-VilleurbanneRecruiting
-
Istituto Ortopedico GaleazziCompletedSmell Disorder | Orthopedic Disorder of SpineItaly
-
Leigh SowerbyFanshawe CollegeRecruiting
-
St. Olavs HospitalNorwegian University of Science and TechnologyCompletedPeople With Normal Sense of SmellNorway
-
University of ReadingUniversity College London Hospitals; University of London; AbScentCompleted
Clinical Trials on No Intervention: Observational Cohort
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
Institut Cancerologie de l'OuestNot yet recruiting
-
University of CalgaryRecruiting
-
Guangzhou Women and Children's Medical CenterNot yet recruitingNEC - Necrotizing Enterocolitis
-
Trakya UniversityRecruitingFrailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture SurgeryFrailty | Hip Fracture | Proximal Femur FractureTurkey (Türkiye)
-
Washington University School of MedicineVanderbilt University Medical Center; University of Abuja Teaching HospitalNot yet recruitingPreeclampsia (PE) | Cardiovascular Biomarkers | Preeclampsia (PE) RiskNigeria
-
Heinrich-Heine University, DuesseldorfRoche Pharma AG; Maria Hilf Clinics GmbH, Mönchengladbach; German Multiple Sclerosis...RecruitingMultiple Sclerosis | Fatigue Syndrome, Chronic | Sleep Disorders | Primary Progressive Multiple Sclerosis | Secondary Progress Multiple Sclerosis | Remitting-Relapsing Multiple SclerosisGermany
-
Instituto de Investigación Sanitaria de la Fundación...Hospital General Universitario Gregorio Marañon; Fundació d'investigació Sanitària... and other collaboratorsRecruiting
-
The First Hospital of Jilin UniversityNot yet recruitingCritical Illness | Adult | ICU
-
The Children's Hospital of Zhejiang University...Not yet recruitingPediatric | Congenital Hydronephrosis | UTD Grading System | Natural ProgressionChina